Celldex Therapeutics, Inc. (CLDX) Stock Forecast Oct. 16, 2026

Our AI ranks Celldex Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

Celldex Therapeutics, Inc. is a mid-cap company with a market capitalization of $2.16B. It ranks number 4 by market capitalization among the 17 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast. Its Net Margin of -191432.5% is the lowest of the 12 peers that report one.

For CLDX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 15.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 25.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)

All daily signals →